A review of pharmaceutical agents and oral bone health: how osteonecrosis of the jaw has affected the field.

Matthew Allen, Salvatore L. Ruggiero

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Just a decade ago, the outlook appeared limitless for the use of bisphosphonates for the treatment of a large number of metabolic bone diseases ranging from osteoporosis to cancer-related bone alterations to oral bone loss. Soon thereafter, however, osteonecrosis of the jaw (ONJ) emerged as a rare but significant condition associated with bisphosphonate treatment. Although many questions remain concerning ONJ, some significant knowledge has been gained over the past decade. Ideas have emerged regarding how to stage and treat the condition, and a number of preclinical models have been developed that will soon begin to speed progress toward understanding the pathophysiology of this condition. Researchers have also discovered that ONJ is not specific to bisphosphonates, as other potent antiremodeling agents have now been associated with the condition. While antiremodeling agents remain essential tools in medicine, ONJ has somewhat slowed the momentum for this drug class, especially as it relates to new and emerging applications. Until more effective prevention or treatment regimens for ONJ are developed, this side effect of remodeling suppression will continue-for better or worse-to have a significant impact on the field. One potential treatment option may be in the form of osteoanabolics. Exciting new data have emerged demonstrating the efficacy of teriparatide (parathyroid hormone) in reversing oral cavity bone loss and even as a potential therapy for ONJ.

Original languageEnglish
JournalThe International journal of oral & maxillofacial implants
Volume29
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Osteonecrosis
Oral Health
Jaw
Bone and Bones
Diphosphonates
Pharmaceutical Preparations
Teriparatide
Bone Neoplasms
Metabolic Bone Diseases
Parathyroid Hormone
Osteoporosis
Mouth
Research Personnel
Medicine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{e9d5c5c059f84b36aa189ee0170ba69b,
title = "A review of pharmaceutical agents and oral bone health: how osteonecrosis of the jaw has affected the field.",
abstract = "Just a decade ago, the outlook appeared limitless for the use of bisphosphonates for the treatment of a large number of metabolic bone diseases ranging from osteoporosis to cancer-related bone alterations to oral bone loss. Soon thereafter, however, osteonecrosis of the jaw (ONJ) emerged as a rare but significant condition associated with bisphosphonate treatment. Although many questions remain concerning ONJ, some significant knowledge has been gained over the past decade. Ideas have emerged regarding how to stage and treat the condition, and a number of preclinical models have been developed that will soon begin to speed progress toward understanding the pathophysiology of this condition. Researchers have also discovered that ONJ is not specific to bisphosphonates, as other potent antiremodeling agents have now been associated with the condition. While antiremodeling agents remain essential tools in medicine, ONJ has somewhat slowed the momentum for this drug class, especially as it relates to new and emerging applications. Until more effective prevention or treatment regimens for ONJ are developed, this side effect of remodeling suppression will continue-for better or worse-to have a significant impact on the field. One potential treatment option may be in the form of osteoanabolics. Exciting new data have emerged demonstrating the efficacy of teriparatide (parathyroid hormone) in reversing oral cavity bone loss and even as a potential therapy for ONJ.",
author = "Matthew Allen and Ruggiero, {Salvatore L.}",
year = "2014",
doi = "10.11607/jomi.te41",
language = "English",
volume = "29",
journal = "International Journal of Oral and Maxillofacial Implants",
issn = "0882-2786",
publisher = "Quintessence Publishing Company",
number = "1",

}

TY - JOUR

T1 - A review of pharmaceutical agents and oral bone health

T2 - how osteonecrosis of the jaw has affected the field.

AU - Allen, Matthew

AU - Ruggiero, Salvatore L.

PY - 2014

Y1 - 2014

N2 - Just a decade ago, the outlook appeared limitless for the use of bisphosphonates for the treatment of a large number of metabolic bone diseases ranging from osteoporosis to cancer-related bone alterations to oral bone loss. Soon thereafter, however, osteonecrosis of the jaw (ONJ) emerged as a rare but significant condition associated with bisphosphonate treatment. Although many questions remain concerning ONJ, some significant knowledge has been gained over the past decade. Ideas have emerged regarding how to stage and treat the condition, and a number of preclinical models have been developed that will soon begin to speed progress toward understanding the pathophysiology of this condition. Researchers have also discovered that ONJ is not specific to bisphosphonates, as other potent antiremodeling agents have now been associated with the condition. While antiremodeling agents remain essential tools in medicine, ONJ has somewhat slowed the momentum for this drug class, especially as it relates to new and emerging applications. Until more effective prevention or treatment regimens for ONJ are developed, this side effect of remodeling suppression will continue-for better or worse-to have a significant impact on the field. One potential treatment option may be in the form of osteoanabolics. Exciting new data have emerged demonstrating the efficacy of teriparatide (parathyroid hormone) in reversing oral cavity bone loss and even as a potential therapy for ONJ.

AB - Just a decade ago, the outlook appeared limitless for the use of bisphosphonates for the treatment of a large number of metabolic bone diseases ranging from osteoporosis to cancer-related bone alterations to oral bone loss. Soon thereafter, however, osteonecrosis of the jaw (ONJ) emerged as a rare but significant condition associated with bisphosphonate treatment. Although many questions remain concerning ONJ, some significant knowledge has been gained over the past decade. Ideas have emerged regarding how to stage and treat the condition, and a number of preclinical models have been developed that will soon begin to speed progress toward understanding the pathophysiology of this condition. Researchers have also discovered that ONJ is not specific to bisphosphonates, as other potent antiremodeling agents have now been associated with the condition. While antiremodeling agents remain essential tools in medicine, ONJ has somewhat slowed the momentum for this drug class, especially as it relates to new and emerging applications. Until more effective prevention or treatment regimens for ONJ are developed, this side effect of remodeling suppression will continue-for better or worse-to have a significant impact on the field. One potential treatment option may be in the form of osteoanabolics. Exciting new data have emerged demonstrating the efficacy of teriparatide (parathyroid hormone) in reversing oral cavity bone loss and even as a potential therapy for ONJ.

UR - http://www.scopus.com/inward/record.url?scp=84900033856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900033856&partnerID=8YFLogxK

U2 - 10.11607/jomi.te41

DO - 10.11607/jomi.te41

M3 - Article

C2 - 24451887

AN - SCOPUS:84900033856

VL - 29

JO - International Journal of Oral and Maxillofacial Implants

JF - International Journal of Oral and Maxillofacial Implants

SN - 0882-2786

IS - 1

ER -